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Abstract: Preeclampsia is a pregnancy-specific disease of high prevalence characterized by the onset
of hypertension, among other maternal or fetal signs. Its etiopathogenesis remains elusive, but it is
widely accepted that abnormal placentation results in the release of soluble factors that cause the
clinical manifestations of the disease. An increased level of soluble endoglin (sEng) in plasma has
been proposed to be an early diagnostic and prognostic biomarker of this disease. A pathogenic
function of sEng involving hypertension has also been reported in several animal models with high
levels of plasma sEng not directly dependent on pregnancy. The aim of this work was to study the
functional effect of high plasma levels of sEng in the pathophysiology of preeclampsia in a model
of pregnant mice, in which the levels of sEng in the maternal blood during pregnancy replicate
the conditions of human preeclampsia. Our results show that wild type pregnant mice carrying
human sEng-expressing transgenic fetuses (fWT(hsEng+)) present high plasma levels of sEng with a
timing profile similar to that of human preeclampsia. High plasma levels of human sEng (hsEng) are
associated with hypertension, proteinuria, fetal growth restriction, and the release of soluble factors
to maternal plasma. In addition, fWT(hsEng+) mice also present placental alterations comparable to
those caused by the poor remodeling of the spiral arteries characteristic of preeclampsia. In vitro and
ex vivo experiments, performed in a human trophoblast cell line and human placental explants, show
that sEng interferes with trophoblast invasion and the associated pseudovasculogenesis, a process
by which cytotrophoblasts switch from an epithelial to an endothelial phenotype, both events being
related to remodeling of the spiral arteries. Our findings provide a novel and useful animal model
for future research in preeclampsia and reveal a much more relevant role of sEng in preeclampsia
than initially proposed.
Keywords: soluble endoglin; placenta; preeclampsia; murine model
1. Introduction
Preeclampsia is a pregnancy-specific disease which affects about 3–5% of all preg-
nancies worldwide [1]. It is the major cause of maternal, fetal, and neonatal mortality in
developed nations. Preeclampsia is characterized by hypertension (>140/90 mmHg) and
proteinuria (>300 mg/24 h), appearing mainly after 20 weeks of pregnancy. In addition,
preeclamptic women can present other alterations such as endothelial dysfunction, as well
as disorders of the liver, kidney, brain, and clotting system [1,2]. Therefore, preeclampsia is
considered to be a complex and multisystem disease [3].
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Despite the abundant literature about the pathophysiology of preeclampsia, its molec-
ular pathogenesis is mostly unknown. It is widely accepted that the placenta is key to the
pathogenesis of this condition, as evidenced by the rapid disappearance of symptoms after
delivery, and their persistence while the placenta is not removed [4,5]. Strong experimental
evidence suggests that placental ischemia, resulting from the inappropriate remodeling of
the maternal spiral arteries, stimulates the release of soluble factors causing hypertension,
renal damage, and other preeclampsia-associated alterations [6,7]. Among the various
factors released from the preeclamptic placenta, there has been increased interest in soluble
endoglin (sEng).
Human sEng can be generated upon a metalloprotease-mediated proteolytic cleavage
acting on the extracellular domain of the full-length membrane bound endoglin (Eng) [8].
Full-length endoglin, a 180 kDa disulfide-linked homodimer, is a type I integral membrane
glycoprotein with a large extracellular domain (561 amino acids), a single hydrophobic
transmembrane domain, and a short cytosolic tail [9]. Eng is very abundant in endothe-
lial cells and is also present in other cell types, including trophoblasts and syncytiotro-
phoblasts [10–12]. Shedding of sEng from these cell types in the placenta has been described
to be mediated by the matrix metalloprotease (MMP)-14 [13–16]. Of note, expression levels
and enzymatic activity of MMP-14 are increased in various conditions related to endothelial
injury, activation, inflammation and senescence, as well as in pregnancy [17–21]. Several
lines of evidence support a functional role of sEng in cardiovascular conditions and dis-
eases, including endothelial dysfunction, anti-angiogenic activity, hypertension, increased
vascular permeability, vascular remodeling, and inflammation-associated leukocyte adhe-
sion and extravasation [8,14,20,22–27]
Several observations have linked high levels of sEng and other vasoactive factors in
maternal circulation with clinical manifestations of preeclampsia [18,28–30]. Thus, sEng
levels in plasma, as well as the ratio between plasma levels of soluble fms-like kinase 1
(sFlt1), a soluble form of the vascular endothelial growth factor (VEGF) receptor type-1, and
placental growth factor (PlGF, a member of the VEGF family) are increased weeks before
the onset of preeclampsia [17,31,32]. Furthermore, an increase of these values correlates
with a higher severity and a worse prognosis of preeclampsia [17,18,33–35]. For this reason,
sEng and sFlt1/PlGF ratio have been proposed to be useful biomarkers for diagnosis and
prognosis of preeclampsia [17,36].
Although the correlation between increased levels of sEng and preeclampsia has been
repeatedly described in the literature, there are only a few reports that have analyzed the
putative role of sEng in the symptoms characteristic of preeclampsia or in the onset of
this disease [14,18,37,38]. In this regard, we previously reported that mice continuously
exposed to high circulating levels of sEng showed preeclampsia-like symptoms such as
hypertension and proteinuria in the absence of pregnancy [14]. In addition, we postulated
that the sEng-induced effect in hypertension was mediated by an upregulation of bone
morphogenetic protein 4 (BMP4) [26]. Unfortunately, none of these studies phenocopied
the maternal syndrome of preeclampsia, since they were not performed in mice with
pregnancy-induced high circulating levels of sEng. Thus, our aim, in this work, was
to study the role of high plasma levels of sEng in the pathophysiology of preeclampsia
in a model of pregnant mice, in which the levels of sEng in the maternal blood during
pregnancy replicate the conditions of human preeclampsia. Our results show that wild type
pregnant mice carrying human sEng-expressing transgenic fetuses present high plasma
levels of human sEng (hsEng) and clinical manifestations associated with the preeclampsia
condition. This animal model also shows placental alterations such as oxidative stress,
inflammation, and reduced pseudovasculogenesis, a process by which cytotrophoblasts
switch from an epithelial to an endothelial phenotype, crucial for remodeling of the spiral
arteries and supply of maternal blood. These findings provide a better understanding of
the role of sEng in the pathophysiology of preeclampsia and have potential implications in
preventive and therapeutic approaches for this condition.
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2. Results
2.1. Wild Type Pregnant Females with hsEng+ Fetuses Show High Plasma Levels of Soluble Eng
The aim of this study was to develop an animal model with increased levels of human
sEng during pregnancy, mimicking the profile of sEng plasma levels in preeclampsia. For
this purpose, a previously reported transgenic mouse line which overexpresses human
sEng (hsEng+) was used [14]. Wild type (WT) female mice were crossed with hsEng+ male
mice, so the WT pregnant females bore both WT and hsEng+ fetuses, and hereinafter are
referred to as fWT(hsEng+). In parallel, WT female mice were crossed with WT male mice,
resulting in pregnant WT females bearing only WT fetuses and named fWT(WT) (Figure 1).
Analysis of plasma samples from pregnant fWT(hsEng+) mice showed increased levels
of hsEng from the 11th day of gestation and this increase was sustained until the end of
pregnancy, similar to human preeclampsia (Figure 2a). As expected, no hsEng was detected
in pregnant fWT(WT) mice.
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Figure 1. Description of the animal model. Wild type (WT) female mice crossed with transgenic
male mice overexpressing human soluble endoglin (hsEng+), named as fWT(hsEng+), carry both WT
and hsEng+ embryos. WT female mice crossed with WT male mice, named as fWT(WT), carry only
WT embryos.
The overall association between plasma levels of hsEng in f T(hsEng+) females and
the growth of fetuses, strongly suggested a fetal source for hsEng, probably from the
fetal placenta. Thus, we checked the expression of hsEng in placentas of five different
fWT(hsEng+) mice litters. We observed that expression levels of hsEng were variable, with
some placentas showing high levels (likely, placentas fro hsEng+ embryos) and others
with low levels and almost no expre sion, likely fro T embryos (Figure 2b).




Figure 2. Pregnant fWT(hsEng+) mice show high plasma levels of soluble endoglin (sEng) and 
signs of preeclampsia. (a) Plasma levels of hsEng in fWT(hsEng+) mice (n = 6) at different time 
points during gestation; (b) qRT-PCR analysis of hEng mRNA expression in placentas from 5 dif-
ferent fWT(hsEng+) mice litters. Each column represents one litter, and each value corresponds to 
one placenta from that litter. Placentas with higher levels of hEng expressions are inferred to be 
from hsEng+ embryos, whereas placentas with almost no expression are inferred to be from WT 
embryos; (c) Systolic arterial pressure of fWT(WT) (n = 9) and fWT(hsEng+) (n = 12) mice at different 
time points during gestation; (d) Urinary protein excretion, normalized to urinary creatinine con-
centration, of fWT(WT) and fWT(hsEng+) at Day 13 (fWT(WT) n = 8 and fWT(hsEng+) n = 9) and Day 
18 (fWT(WT) n = 19 and fWT(hsEng+) n = 21) of gestation; (e) Weight of the litters from fWT(WT) 
and fWT(hsEng+) mice at Day 13 (fWT(WT) n = 5 litters and fWT(hsEng+) n = 6 litters), and Day 18 
(fWT(WT) n = 18 litters and fWT(hsEng+) n = 22 litters) of gestation; (f) Percentage of aborted fe-
tuses over total fetuses observed on Day 13 or Day 18 of gestation; (g) Plasma levels of murine 
sEng in fWT(WT) and fWT(hsEng+) at Day 13 (fWT(WT) n = 12 and fWT(hsEng+) n = 15) and Day 18 
(fWT(WT) n = 10 and fWT(hsEng+) n = 13) of gestation; (h) sFlt1:PlGF ratio in plasma from fWT(WT) 
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Figure 2. Pregnant fWT(hsEng+) mice show high plasma levels of soluble endoglin (sEng) and signs of preeclampsia. (a)
Plasma levels of hsEng in fWT(hsEng+) mice (n = 6) at different time points during gestation; (b) qRT-PCR analysis of hEng
mRNA expression in placentas fr m 5 different fWT(hsEng+) mice litters. Each colum re res ts one litter, and each value
corresponds to one placenta fro that litter. Placentas with high r levels of hEng expressions are inferred to be from hsEng+
embryos, whereas placentas with almost no expression are inferred to be from WT embryos; (c) Systolic arterial pressure of
fWT(WT) (n = 9) and fWT(hsEng+) (n = 12) mice at different time points during gestation; (d) Urinary protein excretion,
normalized to urinary creatinine concentration, of fWT(WT) and fWT(hsEng+) at Day 13 (fWT(WT) n = 8 and fWT(hsEng+)
n = 9) and Day 18 (fWT(WT) n = 19 and fWT(hsEng+) n = 21) of gestation; (e) Weight of the litters from fWT(WT) and
fWT(hsEng+) mice at Day 13 (fWT(WT) n = 5 litters and fWT(hsEng+) n = 6 litters), and Day 18 (fWT(WT) n = 18 litters and
fWT(hsEng+) n = 22 litters) of gestation; (f) Percentage of aborted fetuses over total fetuses observed on Day 13 or Day 18 of
gestation; (g) Plasma levels of murine sEng in fWT(WT) and fWT(hsEng+) at Day 13 (fWT(WT) n = 12 and fWT(hsEng+)
n = 15) and Day 18 (fWT(WT) n = 10 and fWT(hsEng+) n = 13) of gestation; (h) sFlt1: lGF r tio in plas a from fWT(WT) and
fWT(hsEng+) mice at Day 13 (fWT( ) n = 6 and fWT(hsEng+) n = 7) and Day 18 (fWT(WT) n 2 and fWT(hsEng+) n = 11)
of gestation. Mean ± SEM are isplayed. * p < 0.05, ** p < 0.01, and *** p < 0.001 of fWT(hsEng+) vs. fWT(WT).
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2.2. Pregnant fWT(hsEng+) Mice Present Symptoms and Biomarkers of Preeclampsia
Next, we evaluated the relationship between high plasma levels of hsEng and one of
the hallmarks of preeclampsia, i.e., increased arterial pressure. We observed that the arterial
pressure was higher in fWT(hsEng+) than in fWT(WT) pregnant mice from the 13th day of
gestation until the end of pregnancy (Figure 2c). From there on, we took measurements at
two specific time points as follows: (i) on the 13th day, when the highest levels of sEng were
detected and significant differences in blood pressure started to be observed and (ii) on
the 18th day, immediately before the end of the gestation (21 days), to ensure records even
in case of premature birth, and because in fWT(hsEng+) mice many fetuses were already
necrotic at this time point.
Another characteristic clinical manifestation of preeclampsia is proteinuria. We found
that the urinary protein excretion was significantly higher in fWT(hsEng+) than fWT(WT)
at the 18th day of gestation, whereas this difference was not significant at the 13th day of
gestation (Figure 2d). We also assessed whether proteinuria was associated with structural
or functional renal alterations. Glomerular filtration rate, measured as creatinine clearance,
was similar in fWT(hsEng+) as compared with fWT(WT) mice at the end of gestation
(Figure S1a). In addition, upon hematoxylin and eosin (H&E) staining of renal tissue at
the end of gestation, no relevant alterations in kidney structure were observed in either
fWT(hsEng+) or fWT(WT) females (Figure S1b).
Because fetal growth is restricted in preeclampsia, we analyzed this parameter in our
model. Of note, a direct comparison about fetal growth restriction between human and
mouse pregnancy is not easy. Humans are usually uniparous and fetal growth restriction
can only result in a smaller fetus. However, mice, being multiparous, can present the
following different outcomes: (i) proportional reduction of the size in all the offspring; (ii)
reduction of size in part of the offspring, while other fetuses remain normal; and (iii) demise
of some fetuses, maintaining a normal size in the others. For this reason, we considered
that, in mice, the analysis of total litter weight was the most appropriate parameter to
assess fetal growth restriction. Litter weight was significantly lower at Day 18 of pregnancy
in fWT(hsEng+) than in fWT(WT) females (with a reduction of 33%), but this difference was
not significant at Day 13 (Figure 2e). The observed effect on litter weight was due to both
a reduction in the size of viable fetuses and a reduction in the number of viable fetuses
(Figure S2). Thus, the number of aborted fetuses at Day 18 was markedly higher (10-fold
change) in fWT(hsEng+) than in fWT(WT) pregnant females, since this effect was evident
even at Day 13 (Figure 2f).
Next, we assessed the levels of some biomarkers that are characteristic of preeclamp-
sia. Plasma levels of endogenous murine sEng (msEng), were significantly higher in
fWT(hsEng+) than in fWT(WT) pregnant mice at the end of gestation (Day 18), whereas no
significant differences were observed at Day 13 (Figure 2g). Because the ratio sFlt1/PlGF in
plasma has been reported to be an accurate predictor of preeclampsia [39], we also analyzed
plasma levels of sFlt1 and PlGF in our animal model. We observed a significantly higher
sFlt1/PlGF ratio in fWT(hsEng+) than fWT(WT) pregnant mice after 13 and 18 days of
gestation (Figure 2h). These results suggest that pregnancy-induced high levels of plasma
sEng contribute to the release of vasoactive soluble factors in our animal model.
Taken together, these data suggest that WT pregnant female mice carrying hsEng+
fetuses, fWT(hsEng+), are a good model to study the role of sEng in preeclampsia because
they present the most important symptoms and specific biomarkers of the disease, as well
as a temporal development during pregnancy that resembles what happens in human
preeclampsia. Additionally, these evidences demonstrate that increased plasma sEng
triggers some of the symptoms of preeclampsia, suggesting sEng as an active factor in the
progression of the disease.
2.3. Presence of Soluble Endoglin Is Associated with Placental Alterations
Because pathophysiology of preeclampsia is associated with placental alterations, we
analyzed whether sEng could induce these effects in our animal model. In preeclampsia,
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alterations in remodeling of uterine arteries reduce blood flow to the placenta and induce
placental hypoxia [35,36]. A visual display of the mouse uterus shows the necklace-bead
arrangement of the mouse fetuses with their placentas and a large area including the uterine
arteries. Thus, we measured fetal and uterine blood flow, as shown in Figure 3a, by laser
Doppler flowmetry in pregnant mice. No significant differences, in both uterine and fetal
blood flow, were found between fWT(hsEng+) and fWT(WT) mice at either 13 or 18 days
of pregnancy (Figure 3b,c). In addition, placental weight was similar in fWT(hsEng+)
and fWT(WT) pregnant mice at Days 13 and 18 (Figure 3d). Together, these results do
not support a causal relationship between the high levels of plasma sEng and placental
growth restriction.
Oxidative stress and inflammation also play an important role in the pathophysi-
ology of preeclampsia [37–39]. We found that placentas of fWT(hsEng+) mice showed a
significantly higher (four-fold change) lipid peroxidation than those of fWT(WT) animals
at Day 13; but not at Day 18 of pregnancy (Figure 3e). The lack of difference at Day 18
was due to the expected late increase of this parameter in fWT(WT) animals, suggesting
an abnormal early increase of placental lipid peroxidation in fWT(hsEng+) as compared
with fWT(WT) animals (Figure 3e). Moreover, we observed that the expression of inflam-
matory cytokine genes, such as IL-1β and IL-6, was higher (up to four-fold change) in
placenta of fWT(hsEng+) mice as compared with fWT(WT) after 13 and 18 days of pregnancy
(Figure 3f,g).
We also analyzed whether sEng induces morphologic changes in placentas. At Day
13, no relevant changes were observed when comparing placentas from fWT(hsEng+) and
fWT(WT) mice (Figure 4a,b). However, at the end of gestation (Day 18), an increased
number of cell clusters characterized by big cells with a vacuolated cytosol were observed
in fWT(hsEng+) as compared with fWT(WT) mice placentas (Figure 4d, arrows). These
accumulations of clear cells were observed mainly in the basal area of the placenta in both
fWT(hsEng+) and fWT(WT) placentas at Day 13 (Figure 4a,b, arrows), but were rarely seen
in fWT(WT) mice at Day 18 of pregnancy (Figure 4c). The area occupied by these clear cells
in the placenta at Day 13 of pregnancy was similar in fWT(hsEng+) and fWT(WT) pregnant
females. Nonetheless, at Day 18, a marked decrease (with a reduction of 80%) in the area
covered by clear cells was observed in fWT(WT) placentas, whereas only a slight decrease
(reduction of 33%) was observed in fWT(hsEng+) placentas. Thus, the area occupied by
clear cells at Day 18 was significantly higher in fWT(hsEng+) than in fWT(WT) females
(Figure 4e).
Interestingly, the size and appearance of these clear cells suggest that they are glycogen-
containing trophoblasts (GLYTs). GLYTs are trophoblast-type cells of unknown origin that
appear in the junction zone of the murine placenta. In a normal murine pregnancy, GLYTs
begin to accumulate glycogen and can be found as tightly packed clusters embedded within
spongiotrophoblast cells until 12.5 days of gestation, while their number steadily decrease
until the end of pregnancy [40–42]. However, in our fWT(hsEng+) model of preeclampsia,
the number of these GLYT-like clusters at the end of pregnancy was markedly higher than
in fWT(WT) mice. In order to confirm that these highly vacuolated cells were indeed GLYT,
we performed periodic acid-Schiff (PAS) stain in placental slides. In fact, polysaccharide
accumulations, most probably glycogen, were observed in the cytoplasm of these cells
(Figure 4g,h). To further demonstrate that these cells were indeed GLYTs, the content of
glycogen in placentas was measured at Day 18 of gestation. We observed that the amount of
glycogen tended to be higher in fWT(hsEng+) than in fWT(WT) females’ placentas, although
this difference did not reach statistical significance (Figure 4f).
There are accumulating data to suggest that changes in placental glycogen deposition
is a hallmark feature of a compromised pregnancy associated with fetal growth restric-
tion and, paradoxically, with fetal overgrowth [43]. Overall, the above data support the
hypothesis that high plasma levels of sEng present in our animal model induce structural
placental alterations.
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Figure 3. Pregnant fWT(hsEng+) mice present placental alterations. (a) Representative image of the
analysis of placental and fetal perfusion by laser Doppler imaging. For each scan, the algorithm builds
up a color-coded image representing tissue perfusion (left) and records a color photograph at the
sam ti e (right). Perfusion was determined in two different are s defined by col r phot graph, i.e.,
uterine area and fetal area. As shown in t e scale, the pseudocolor ranges f om left to right, therefore,
blue represents the lowest perfusion and red the highest perfusion; (b) Quantification of the uterine-
area perfusion from fWT(WT) and fWT(hsEng+) mice at Day 13 (fWT(WT) n = 7 and fWT(hsEng+)
n = 7) and Day 18 ((fWT(WT) n = 11 and fWT(hsEng+) n = 15) of gestation; (c) Quantification of the
fetal-area perfusion from fWT(WT) and fWT(hsEng+) mice at Day 13 (fWT(WT) n = 7 and fWT(hsEng+)
n = 7) and Day 18 (fWT(WT) n = 11 and fWT(hsEng+) n = 15) of gestation; (d) Weight of the placentas
from fWT(WT) and fWT(hsEng+) mice at Day 13 (fWT(WT) n = 7 and fWT(hsEng+) n = 7) and Day 18
(fWT(WT) n = 9 and fWT(hsEng+) n = 8] of gestation; (e) Lipid peroxidation, measured as presence of
thiobarbituric acid-reactive substances (TBARS), of placentas from fWT(WT) and fWT(hsEng+) mice
at Day 13 (fWT(WT) n = 20 and fWT(hsEng+) n = 21) and Day 18 (fWT(WT) n = 13 and fWT(hsEng+)
n = 12) of gestation; (f) qRT-PCR analysis of IL-1β expression in the placentas from fWT(WT) and
fWT(hsEng+) mice at Day 13 (fWT(WT) n = 12 and fWT(hsEng+) n = 13) and Day 18 (fWT(WT) n = 12
and fWT(hsEng+) n = 15) of gestation; (g) qRT-PCR analysis of IL-6 expression in the placentas from
fWT(WT) and fWT(hsEng+) mice at Day 13 (fWT(WT) n = 12 and fWT(hsEng+) n = 13) and Day 18
(fWT(WT) n = 12 and fWT(hsEng+) n = 15) of gestation. Mean ± SEM are displayed. ** p < 0.01 and
*** p < 0.001 of fWT(hsEng+) vs. fWT(WT).
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(H&E) staining of placentas from fWT(WT) and fWT(hsEng+) mice at Day 13 (a,b) and Day 18 (c,d)
showing the presence of clusters of glycogen-containing trophoblast (GLYT)-like cells in the basal area
of some placentas (arrows); (e) Quantification of the area occupied by GLYT-like clusters in placentas
from fWT(WT) and fWT(hsEng+) mice at Day 13 (fWT(WT) n = 20 and fWT(hsEng+) n = 17) and Day
18 (fWT(WT) n = 13 and fWT(hsEng+) n = 16) of gestation; (f) Glycogen content in placentas from
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(PAS) staining of placentas from fWT(WT) and fWT(hsEng+) mice at Day 18 colocalizing high levels of
polysaccharides with GLYT-like clusters; (i,j) Immunohistochemical staining for HIF-1α of placentas
from fWT(WT) and fWT(hsEng+) mice at Day 18 showing nuclear HIF-1α expression in GLYTs from
fWT(hsEng+). Mean ± SEM are displayed. ** p < 0.01 of fWT(hsEng+) vs. fWT(WT).
Finally, we analyzed whether high plasma levels of sEng were associated with pla-
cental hypoxia. Under hypoxic conditions, HIF-1α migrates to the nuclei, therefore, we
evaluated the nuclear staining of HIF-1α by immunohistochemistry. Counterstaining with
hematoxylin allowed the visualization of blue nuclei, as well as the accumulations of clear
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cells previously characterized as GLYT cells. Nuclear HIF-1α appearance at Day 13 was
infrequent in most placental cells of both types of animals, fWT(hsEng+) and fWT(WT)
(data not shown). However, at Day 18, the nuclear expression of HIF-1α was very promi-
nent in certain areas of fWT(hsEng+) placentas, while it remained infrequent in fWT(WT).
Interestingly, these hypoxic cells were restricted to the clusters of GLYT cells that are rare
in fWT(WT) placentas (Figure 4i,j).
2.4. Soluble Endoglin Modifies Cytotrophoblast Cell Biology
To further study the effect of sEng in placental functions, we used a human trophoblast
cell line (JAr cells) and human placental explants. JAr cells were treated with 100 ng/mL of
recombinant human soluble endoglin (rhsEng) and cell proliferation, migration, invasion,
and death were analyzed. We observed that treatment with rhsEng significantly reduced
cell proliferation in about 10–20%, as measured by MTT uptake (Figure 5a) and BrdU
incorporation (Figure 5b). In order to confirm that these differences were not due to
an increment of cell death, cell necrosis and apoptosis were evaluated. Cell necrosis
was assessed by measuring the release of lactate dehydrogenase (LDH) to the culture
medium. The amount of LDH released by either rhsEng-treated or non-treated cell was
similar, suggesting that sEng does not induce trophoblast necrosis (Figure 5c). Moreover,
cell apoptosis was assessed measuring the activity of the effector caspase-3 after 48 h
stimulation with rhsEng. Our results showed that levels of activated caspase 3 were similar
in the cells treated or not with rhsEng (Figure 5d). Therefore, the inhibitory effect of sEng
on cell proliferation was not due to increased cell death.
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Figure 5. Soluble endoglin modifies cytotrophoblast cell biology. (a,b) Effect of rhsEng on JAr cell proliferation measured by
MTT assay after 5 days in culture (n = 5) (a) or BrdU incorporation during 2.5 h (b) (n = 5); (c) Effect of rhsEng on trophoblast
cell necrosis evaluated measuring extracellular levels of lactate dehydrogenase (LDH) of JAr cells treated or not with rhsEng
( = 4); (d) Caspase activity in cell lysates of JAr cells treated or not with rhsEng (n = 7); (e) qRT-PCR a alysis of PECAM1,
VE-cadherin, and E-cadherin expression in human placental extracts treated or not with rhsEng (n = 6); (f) Quantification
of JAr inv siveness through the Matrigel®-c ated transwell in fet l bovine serum (FBS) gradi nt, with or without rhsEng
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A key function of trophoblasts is to collaborate in the remodeling of the spiral arteries,
and alterations in this process are a common feature of pregnancy pathologies such as
preeclampsia [40]. It has been described that trophoblasts undergo pseudovasculogenesis,
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a switching process by which the trophoblast changes its phenotype, reducing epithelial
receptors and acquiring endothelial-related receptors [41]. This pseudovasculogenesis
process is associated with trophoblast invasiveness, which is necessary for the correct
remodeling of spiral arteries, and is defective in preeclampsia, further suggesting its
functional importance [41–43].
Thus, we analyzed the effect of sEng on the pseudovasculogenesis of trophoblasts in
placental explants. We found that treatment with 100 ng/mL of rhsEng led to decreased
PECAM1 and VE-cadherin and increased E-cadherin mRNA expression, endothelial and
epithelial cell receptors, respectively (Figure 5e). These results suggest that the pseudovas-
culogenesis process is impaired in the presence of sEng and that the resulting phenotype
is similar to that of invasive cytotrophoblasts in preeclampsia [41]. Since pseudovascu-
logenesis is also linked with trophoblast invasion, we assessed the effect of sEng in this
process using a transwell cell migration assay. Invasiveness of JAr cells through Matrigel®
was significantly diminished after addition of rhsEng (Figure 5f). This inhibitory effect
was dependent on the presence of extracellular matrix, since a similar experiment without
Matrigel® showed no differences between treated or untreated cells (Figure 5g).
3. Discussion
The presence of high circulating levels of sEng in preeclampsia has been widely de-
scribed, and therefore it has been proposed as an early diagnostic and prognostic biomarker
of this disease [18,44,45]. Moreover, several studies in animal models have demon-
strated that increased plasma levels of sEng could play a pathogenic role in preeclamp-
sia [14,18,24,26]. However, the animal models used up to date might not be wholly repre-
sentative of the actual disease, as the symptoms associated with increased plasma levels of
sEng in those models were not dependent on gestation, and only phenocopied the so-called
second step of the disease, related to the systemic mother’s response and associated clinical
symptoms [46]. Thus, we have developed a murine model of preeclampsia in which plasma
levels of sEng are normal before pregnancy, but they increase during the pregnancy, as
in the human disease. In our experimental model, pregnant fWT(hsEng+) mice showed
an increase in plasma hsEng levels from the 11th day of gestation and this increase was
maintained until the end of pregnancy. This timing is similar to that of human preeclampsia
because placentation in mice ends on Day 10.5 and it is equivalent to the beginning of the
second trimester of gestation in humans [47] and it is at this time point when plasma sEng
levels are increased in human preeclampsia [37,44].
In our mouse model of preeclampsia, pregnant fWT(hsEng+) mice present progressive
hypertension and proteinuria, as well as fetal growth reduction, which are typical features
of preeclampsia [47]. While plasma levels of sEng were already increased halfway through
the gestation period, both arterial pressure and proteinuria were higher in hsEng+ than in
WT pregnant females only in the last week of gestation. Thus, in this experimental model
of preeclampsia, plasma levels of sEng maintained their role as predictive biomarkers
of the disease and they were confirmed as a contributor for blood pressure increase and
proteinuria development. Moreover, our results suggest that the contribution of high levels
of sEng to the preeclampsia phenotype is not immediate but needs a sustained increase
of plasma sEng. Interestingly, we recently described that sEng induced the expression
of BMP4 which, in turn, mediated the sEng-dependent effect in hypertension [26]. The
existence of this intermediate may account for the observed delay between the appearance
of increased plasma sEng levels and an increase in blood pressure.
The ratio between plasma levels of sFlt1 and PlGF is also increased before the onset
of human preeclampsia and, together with the plasma concentration of sEng, has been
proposed to be a useful biomarker for diagnosis and prognosis of preeclampsia [17,36].
Similarly, in our model of fWT(hsEng+) mice, higher plasma levels of endogenous sEng
and higher sFlt1/PlGF ratios were observed as compared with fWT(WT) pregnant mice,
supporting its validity as a model of preeclampsia. The increase of plasma levels of sEng
has been described in different animal models of preeclampsia such as placental ischemia
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in pregnant rats due to the reduction of uterine perfusion (RUPP) [7] or feto-placental
expression of the transcription factor STOX1 in transgenic mice [48], both characterized
by the presence of placental abnormalities [49]. Furthermore, several in vitro studies have
shown an increased release of sEng by trophoblasts subjected to hypoxia, oxidative stress,
or inflammation [14,50,51]. Interestingly, our results show that placentas of fWT(hsEng+)
mice present continuous inflammation together with an early increase of oxidative stress.
While we did not find a reduction in placental blood supply in our animal model, these
placental alterations may, based on the above results, have entailed a further increase in
sEng levels and in the sFlt1/PlGF ratio.
The defective development of the placenta plays a key role in the origin of preeclamp-
sia [4,52]. Thus, the disease is apparently associated with a defective remodeling of uterine
spiral arteries that maintains these vessels with a low capacitance, impeding the increase
of blood flow to the placenta that is necessary for a healthy pregnancy [53–55]. Arterial
remodeling occurs when extravillous cytotrophoblasts (EVCT), which are around the spi-
ral arteries, invade the vessel wall and reach their inner face, temporarily substituting
the endothelial cells and leading to vessels with lower resistance, and thus higher blood
flow, in a process called pseudovasculogenesis [41,53–55]. This process is associated with
changes in the expression of adhesion molecules such as cell adhesion molecules (CAMs),
integrins, and cadherins. Thus, EVCT, with an epithelial phenotype defined by the ex-
pression of E-cadherin and β4 and β5 integrins, becomes invasive and differentiates to
endovascular cytotrophoblasts (enCT) with a more endothelial phenotype, characterized by
the expression of VE-cadherin, CAMs, as well as α1 and β3 integrins [41]. On the contrary,
in preeclampsia, where this process is altered, preeclamptic placentas present a strong
staining of E-cadherin and a low staining of VE-cadherin and PECAM resulting in less
invasive cytotrophoblasts [41–43]. Compatible with these findings, our results showed that
human placental explants incubated with sEng have increased expression of E-cadherin,
as well as lower expression of PECAM1 and VE-cadherin as compared with explants
incubated without sEng. Moreover, the presence of sEng reduced both proliferation and
invasiveness of the trophoblast cell line JAr. Hence, it can be speculated that high sEng
levels modify the pseudovasculogenesis process, maintaining the epithelial phenotype,
while weakening the endothelial-like phenotype of the trophoblasts, and thus reducing
their invasive ability. In this regard, the presence of GLYTs clusters at the end of gestation
in fWT(hsEng+) mice could be related to deficient trophoblasts migration/invasion to the
maternal decidua, and thus to impaired pseudovasculogenesis, as observed in our in vivo
and in vitro studies. In the rodent’s placenta, GLYT cells share a common lineage with
the EVCT [56,57]. Around the seventh day of gestation, GLYTs appear in the junctional
zone (JZ) of the placenta [58,59]. From the 10th to the 12th day, GLYTs begin to accumulate
glycogen and can be found as clusters embedded within spongiotrophoblasts (SpT). After
the 13th day, GLYTs begin to invade the interstitium migrating into the maternal decidua
and congregate around spiral arteries [57,60–62]. In our experimental model, a decrease
in the number of GLYT clusters in the placenta in the last days of gestation in pregnant
fWT(WT) but not in fWT(hsEng+) mice was observed. These GLYT clusters present high
nuclear expression of HIF-1α suggesting that they are undergoing hypoxia. However, this
expression pattern of HIF-1α was not observed in the surrounding trophoblasts, suggesting
that hypoxia occurs only in the GLYTs. Of note, when analyzed by laser Doppler, no statis-
tically significant differences, in fetal or in placental blood flow which could explain an
ischemic setting, were observed between fWT(hsEng+) and control mice. Thus, we hypoth-
esize that a discrete small reduction in total placental blood flow in the fWT(hsEng+) mice
may not be enough to induce hypoxia in the spongiotrophoblasts, with a low metabolic
rate, but may be sufficient to induce hypoxia in the GLYTs, that are cells metabolically very
active [43]. However, further experiments, which are beyond the scope of this study, would
be needed to fully test this hypothesis. In preeclampsia, the onset of placental hypoxia
leads to the appearance of oxidative stress, which may cause damage to proteins, lipids, or
DNA, as well as endothelial dysfunction and endovascular systemic inflammation [63]. In
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line with the literature, we found an increase in lipid peroxidation that occurred earlier in
fWT(hsEng+) than in fWT(WT) pregnant mice. In addition, we observed, in the placenta of
fWT(hsEng+) mice, an increased expression of proinflammatory cytokines such as IL-6 and
IL-1β as compared with fWT(WT). So far, most experimental animal studies have shown
that increased inflammation and oxidative stress were associated with increased release
of sEng [14,50]. Therefore, increased ROS and proinflammatory cytokines observed in
our model by elevated levels of sEng could promote further increases in plasma levels of
sEng which, in turn, may lead to a positive feedback loop, thus, enhancing the disease
progression.
In conclusion, our study describes a new model of pregnancy-associated increase
of sEng levels, supporting the pathogenic contribution of sEng to preeclampsia. We
report, for the first time, that sEng not only participates directly in the maternal symptoms,
such as hypertension or proteinuria, but also gives rise to alterations in the placental
function and structure related to the development of preeclampsia. These alterations
could be responsible for a further increase in the levels of sEng, thus, giving rise to a
positive feedback loop that could contribute to aggravate the disease (Figure 6). According
to our results, sEng appears to have a much more relevant role in preeclampsia than
initially proposed, opening new therapeutic avenues of research based on sEng. It can
be postulated that, while sEng per se might not be the initial trigger of preeclampsia, it
may act in concert with additional pathophysiological stimuli, thus, contributing to a full
disease phenotype. Overall, we believe that the development of this novel animal model
represents an important advance for future research and discovery in preeclampsia.
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Figure 6. Hypothetical model of sEng role in preeclampsia. The high levels of soluble endoglin (sEng)
are directly involved in the appearance of maternal preeclampsia symptoms, such as hypertension or
proteinuria (dashed arrowhead on the right), as shown in non-pregnant animal models. But during
pregnancy, sEng can also induce placental alterations such as inflammation, oxidative stress, and
hypoxia. These alterations seem to be due to a defective pseudovasculogenesis and a diminished
proliferative and invasive capacity of trophoblasts, and lead to the appearance of maternal symptoms,
as well as the abnormal levels of soluble factors. As sEng is one of these factors whose expression
is increased, it could trigger a positive feedback loop that may contribute to aggravate the disease
(continuous arrowhead on the left). Created with BioRender.com.
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4. Materials and Methods
4.1. Animals and Study Design
A mouse line that overexpresses human soluble endoglin (hsEng) on a CBA ×C57BL/6J
background (hsEng+) was generated at the Genetically Modified Organisms Generation
Unit (University of Salamanca, Spain), as previously described [14]. A breeding colony
of adult hsEng+ mice has been maintained in the pathogen-free facilities for genetically
modified mice at the University of Salamanca and backcrossed with CBA×C57Bl/6 mice
for nine generations. Routine genotyping of DNA, isolated from mouse tail biopsies, was
performed by PCR using the primers previously reported [14]. For the present study, male
transgenic hsEng+ mice were crossed with female wild type (WT) mice (CBA×C57BL/6J
background). Pregnant WT female resulting from this cross were called fWT(hsEng+). Preg-
nant mice resulting from the cross between male WT with female WT mice (CBA×C57BL/6J
background), were called fWT(WT) (Figure 1).
For animal anesthesia, 2% isoflurane in oxygen was used. During recovery from the
anesthesia, heat was provided and, when necessary, a dose of buprenorphine (0.05 mg/kg)
was subcutaneously administered. Animals were sacrificed by CO2 inhalation or cervical
dislocation, depending on the age and the experiment requirements.
All animal procedures were conducted in strict compliance with the European Commu-
nity Council Directive (2010/63/EU) and Spanish legislation (RD1201/2005 and RD53/2013).
The protocols were approved by the University of Salamanca Ethical Committee (Permit
Number: 006–201400038812, date 22 October 2014). Animal selection was genotype based
and no randomization or blinding was performed. Animals were housed under specific
pathogen-free conditions at the University of Salamanca facilities (ES-119-002001 SEARMG),
in a temperature-controlled room with 12 h light/dark cycle and reared on standard chow
and water provided ad libitum.
4.2. Enzyme-Linked Immunosorbent Assays (ELISA)
Blood samples were obtained from the jugular vein of anesthetized mice in tubes
containing 1 mM EDTA. Blood samples were centrifuged at 1600× g for 15 min at 4 ◦C,
and plasma was collected. Concentrations of human sEng were determined by Quantikine
Human Eng/CD105 (R&D Systems, Minneapolis, MN, USA). Mouse sEng concentration
was determined by Quantikine Mouse Eng/CD105 (R&D Systems). Concentration of
sFLT1 was determined with the Flt1 Mouse ELISA kit (Abnova, Taipei, Taiwan). PlGF
concentration was measured using a Mouse PLGF ELISA kit (Abcam, Cambridge, UK). All
immunoassay kits were used following the manufacturers’ instructions.
4.3. Arterial Blood Pressure Measurement
Systolic blood pressure was monitored in conscious pregnant mice with an automated
multichannel system by using the tail-cuff method and a photoelectric sensor (Niprem
546, Cibertec, Madrid, Spain), as previously described [64,65]. Animals were previously
accustomed for several days and measures were collected at 0, 6, 10, 13, 14, and 18 days
of gestation.
4.4. Renal Function Measurement
Renal function was analyzed, as previously described [66]. Briefly, to determine
glomerular filtration rate and protein levels in urine, pregnant mice were allocated in
individual metabolic cages for urine sample collection during 24 h. Animals were accus-
tomed to being kept in metabolic cages for two days and urine was collected on the third
day. Plasma and urine creatinine were quantified using a commercial kit (QuantichromTM
Creatinine Assay, Biossay System, Hayward, CA, USA), following the manufacturer’s
instructions. Creatinine clearance (ClCr) was calculated as follows: CrU × 24 h urine
output × CrP−1. Proteinuria was assessed by measuring urinary protein/creatinine ratio.
Protein concentration was measured using the Bradford method [67].
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4.5. Gene Expression Assays
For qRT-PCR analysis, total RNA was isolated using Nucleospin RNAII (Macherey-
Nagel, Düren, Germany) and single-strand cDNA was generated from 500 ng of total
RNA using iScript RT Supermix 5× (Bio-Rad, Hercules, CA, USA), according to the
manufacturer’s instructions. qRT-PCR was performed in triplicate. Each 20 µL reaction
contained 1 µL of cDNA, 400 nM of each primer, and 1x iQ SybrGreen Supermix (Bio-Rad).
Standard curves were run for each transcript to ensure exponential amplification and
to rule out nonspecific amplification. The reactions were run on an iQ5 Real-time PCR
detection system (Bio-Rad). Gene expression results were normalized to β-actin (Actb) for
mouse genes and to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) for human genes.
The primers used are listed in Table 1.
Table 1. Primer sequences.
Gene (Protein) qPCR Primers Organism
ENG (endoglin) Forward-AGGTGCTTCTGGTCCTCAGTReverse-CCACTCAAGGATCTGGGTCT Human
Il1b (Interleukin-1β) Forward-GCCTGTGTTTTCCTCCTTGCReverse-TGCTGCCTAATGTCCCCTTG Mouse
Il6 (Interleukin-6) Forward-TCCAGTTGCCTTCTTGGGACReverse-AGTCTCCTCTCCGGACTTGT Mouse
Actb (β-actin) Forward-TCTACAAATGTGGCTGAGGACTReverse-GAGGGACTTCCTGTAACCACTT Mouse
CADH1 (E-cadherin) Forward-CAAGCTATCCTTGCACCTCAGReverse-GCATCAGAGAACTCCTATCTT Human
CADH5 (VE-cadherin) Forward-TGGTCACCCATGCATCTTCCReverse-CCATGACGAAGGGTGAGCTT Human
PECAM1 (CD31) Forward-TGCCGTGGAAAGCAGATACReverse-GGAGCAGGGCAGGTTCATAA Human
GAPDH Forward-CAATGACCCCTTCATTGACCReverse-GACAAGCTTCCCGTTCTCAG Human
4.6. Placental and Fetal Perfusion
At Days 13 and 18 after pregnancy, animals were anesthetized as described above. A
midline abdominal incision was done to expose the uterus. We assessed microvascular
placental and fetal perfusion using laser Doppler imaging (moorLDI, Moor Instruments
Ltd., Devon, UK)), as previously described [68]. In brief, a helium-neon laser scans the
surface of the tissue and light, and ultrasound signal, back-scattered from moving erythro-
cytes, is shifted in frequency by an amount proportional to their velocity, according to the
Doppler principle. These Doppler shifts are collected and processed by the instrument. For
each scan, the computer builds up a color-coded image representing tissue perfusion in
two dimensions. This relative measure of flow is expressed in arbitrary perfusion units.
The laser head was positioned 25 cm from the measurement tissue area, and each scan
took ~5 s. The recorded images were analyzed using dedicated image-processing software
(moorLDLS, Moor Instruments Ltd., Devon, UK).
4.7. Histological Studies
Placenta and kidney tissue were fixed in 4% neutral-buffered formalin and subse-
quently embedded in paraffin. Three µm thick sections were stained with hematoxylin and
eosin (H&E) using a standard protocol. Tissue sections were processed for immunohisto-
chemistry as follows: Endogenous peroxidase was blocked with 3% hydrogen peroxide,
followed by immunohistochemical staining for HIF-1α (antibody 113642, 1:750 dilution,
Abcam) as reported [69]. Periodic acid–Schiff stain (PAS) is a standard histological stain
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used to detect polysaccharides such as glycogen, and glycoproteins, glycolipids, and
mucins in tissues. These compounds react with the Schiff reagent to produce a characteris-
tic positive magenta color. For this stain, we used a commercial PAS staining kit (101646,
Sigma-Aldrich, St. Louis, MO, USA), following the manufacturer’s instructions. Sections
were analyzed by light microscopy and images were taken with an Olympus DP70 BX51
microscope (Olympus, Tokyo, Japan).
4.8. Placental Biochemical Determinations
For glycogen determination, freshly collected placental samples were homogenized
in PBS and centrifuged at 10,000 g for 10 min at 4 ◦C. Subsequently, the glycogen concen-
tration in that supernatant was determined and corrected for the protein concentration.
The glycogen concentration was determined using the colorimetric Glycogen Assay Kit
(Cell Biolabs, Inc., San Diego, CA, USA), following the manufacturer´s instructions. Pro-
tein concentration was determined by the method described above in the Section 4.4 for
proteinuria measurement.
Lipid peroxidation, a useful marker for oxidative stress, was assessed as thiobarbituric
acid-reactive substances (TBARS) in placental homogenates, as previously described [70],
and corrected for the protein concentration of the homogenate.
4.9. Cell Culture and Placental Explants
The human placental choriocarcinoma cell line JAr (Lonza, Walkersville, MD, USA)
and placental explants were used for in vitro experiments. The JAr cell line expresses
endoglin and has been used as a model in trophoblast studies [71]. JAr cells were cul-
tured in RPMI-1640 medium with glucose (4.5 g/L) and penicillin-streptomycin (Gibco,
Thermofisher, Pittsburgh, PA, USA) in the presence of 10% fetal bovine serum (FBS) (Gibco).
Human fresh placental explants were collected in the delivery room (University Hospi-
tal, Salamanca, Spain), within 30 min of delivery from patients without complications. After
removal of decidua and large vessels, 2 cm of tissue was cultured in RPMI-1640 medium
without FBS. When necessary, JAr cells and explants were incubated with 100 ng/mL
recombinant human sEng (rhsEng, 1097-EN, R&D Systems, Minneapolis, MN, USA).
4.10. Cell Proliferation and Apoptosis Assays
For proliferation assays, 5 × 103 cells per well were seeded in 24-well plates in RPMI-
1640 with 10% FBS containing or not 100–200 ng/mL rhsEng at 37 ◦C with 5% CO2 for
24 h. Proliferation was determined by incubating cell cultures with 0.5 mg/mL 3-[4.5-
dimethylthiazol-2-yl]-2.5-diphenyl tetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis,
MO, USA) for 4 h. Then, 10% SDS in 0.01M HCl was added at a 1:1 (v/v) ratio and left
overnight at 37 ◦C. Finally, absorbance was measured at 570 nm. The effect of soluble
Eng on trophoblast proliferation was also measured using a commercial BrdU (5-bromo-
2-deoxyuridine) ELISA kit (Roche, Basilea, Switzerland), following the manufacturer’s
instructions.
Apoptosis was assessed by measuring activated caspase-3 with a commercial caspase-
3 assay kit (Innoprot, Derio, Spain) and cell necrosis was assessed by the release of LDH to
the culture medium, as measured by the ScienCell™ LDH Citotoxicity Assay (Innoprot),
following manufacturer´s instructions.
4.11. Transwell Migration and Invasion Assays
The transwell cell migration assay measures the capability of cells to migrate through
the transwell membrane, whereas the transwell cell invasion assay measures the invasion
of cells through the extracellular matrix and transwell membrane. Cells marked with the
cell-permeant dye calcein-AM (Sigma-Aldrich, St. Louis, MO, USA) were diluted in serum-
free culture medium and plated on top of the filter membrane in a transwell with 8 µm
pore size (FluoroBlock™, Corning, Corning, NY, USA) placed in a 24-well plate. Culture
medium containing 10% FBS was added to the bottom chamber and plates were incubated
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at 37 ◦C and 5% CO2 to allow the cells to settle down. For invasion assays, Matrigel® (R&D
Systems, Minneapolis, MN, USA) was loaded on top of the transwell membrane and cells
were added on top of the Matrigel coating to simulate invasion through the extracellular
matrix. The fluorescence was measured at the bottom of the plate at 8 h (migration assays),
and at 24 h for (invasion assays), and then normalized against the control condition.
4.12. Data Presentation and Statistical Analysis
Images shown are representative and all data, except those obtained by qRT-PCR, are
expressed as the mean ± SEM. qRT-PCR results are represented in box plots that show the
median and the 25th–75th percentiles, with whiskers showing the 10th–90th percentiles.
In vitro experiments were repeated at least three times. For data related to controls, such as
qRT-PCR, log transformation was performed before the statistical study for normalization.
The D’Agostino–Pearson normality test was applied to the datasets prior to statistical
comparisons. The Kolmogorov–Smirnov test was used for small datasets. For normally
distributed datasets, Student’s t-test was used. The Mann–Whitney U test was used as
the nonparametric test. One-way or two-way ANOVA was used to assess the differences
between groups in the time-course experiments. Sidak’s post-hoc test was used after
ANOVA. The following three levels of significance were defined: * p < 0.05, ** p < 0.01, and
*** p < 0.001. All analyses and graphs were performed using GraphPad Prism version 7.0.0
for Windows (GraphPad Software, San Diego, California USA, www.graphpad.com).
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-0
067/22/1/165/s1, Figure S1: Renal function in pregnant fWT(hsEng+) mice, Figure S2: Pregnant
fWT(hsEng+) mice present reduced fetal weight and number of viable fetuses.
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Abbreviations
BMP4 Bone morphogenetic protein 4





FBS Fetal bovine serum
fWT(hsEng+) Pregnant WT females bearing both WT and hsEng+ fetuses
fWT(WT) Pregnant WT females bearing only WT fetuses
GLYT Glycogen-containing trophoblast
H&E Hematoxylin and eosin
HIF-1α Hypoxia-inducible factor 1 alpha




msEng Murine soluble endoglin
MTT 3-[4.5-Dimethylthiazol-2-yl]-2.5-diphenyl tetrazolium bromide
PAS Periodic acid-Schiff
PlGF Placental growth factor
qRT-PCR Quantitative reverse transcription polymerase chain reaction
rhsEng Recombinant human soluble endoglin
ROS Radical oxygen species
RUPP Reduction of uterine perfusion
sEng Soluble endoglin
SEM Standard error of the mean
sFlt1 Fms-like kinase 1
SpT Spongiotrophoblasts
VEGF Vascular endothelial growth factor
WT Wild type
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